Specifically, YAP activation is associated with reduced patient survival in CRC, NSCLC, HCC, ovarian cancer, esophageal squamous cell carcinoma, and urothelial carcinoma of the bladder [60-63,74,86,87]. Here, YAP1 is linked to colorectal carcinoma.